News & Updates

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

24 Jun 2025 by

In the first interim analysis of the phase III KEYNOTE-689 trial, pembrolizumab improves event-free survival (EFS) and major pathological response (mPR) rate, independent of CPS*, when added to standard-of-care (SoC) treatment for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC).

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

24 Jun 2025

Injectable extended-release naltrexone poses no hepatotoxicity signal in advanced ALD

24 Jun 2025

The use of the injectable extended-release naltrexone for alcohol use disorder in patients with advanced alcohol-associated liver disease (ALD) does not appear to carry a substantial hepatotoxicity or liver decompensation risk, according to a study.

Injectable extended-release naltrexone poses no hepatotoxicity signal in advanced ALD

24 Jun 2025

Carvedilol trumps propranolol in preventing decompensation in cirrhosis

23 Jun 2025

A recent study has provided data bolstering the current recommendation of using carvedilol to prevent a first decompensation of cirrhosis in patients with compensated cirrhosis.

Carvedilol trumps propranolol in preventing decompensation in cirrhosis

23 Jun 2025

Penpulimab extends survival in R/M nasopharyngeal carcinoma

23 Jun 2025 by

The use of penpulimab, in combination with gemcitabine and cisplatin or carboplatin, as first-line treatment for recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) provides statistically significant and clinically meaningful benefit, according to a study presented at AACR 2025.

Penpulimab extends survival in R/M nasopharyngeal carcinoma

23 Jun 2025

IgAN drug hits target in phase III study

23 Jun 2025 by

The selective immunoglobulin (Ig)G2 antibody sibeprenlimab reduces proteinuria in individuals with IgA nephropathy (IgAN) in an interim analysis of the phase III VISIONARY study.

IgAN drug hits target in phase III study

23 Jun 2025

Original New Drug Application Approvals by US FDA (16-31 May 2025)

23 Jun 2025

New drug applications approved by US FDA as of 16-31 May 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 May 2025)

23 Jun 2025

Onradivir as good as oseltamivir for acute, uncomplicated flu

22 Jun 2025

In the treatment of adults with acute, uncomplicated influenza infections, onradivir appears to provide similar curative efficacy as oseltamivir while having an acceptable safety profile, as shown in a phase III study.

Onradivir as good as oseltamivir for acute, uncomplicated flu

22 Jun 2025

Bispecific antibody overcomes P. aeruginosa infection in patients with bronchiectasis

20 Jun 2025 by

The bispecific antibody gremubamab, which targets two proteins on the surface of Pseudomonas aeruginosa, has been shown to substantially reduce bacterial load and improve quality of life for infected bronchiectasis patients in the phase II GREAT-2 study.

Bispecific antibody overcomes P. aeruginosa infection in patients with bronchiectasis

20 Jun 2025

Is it safe to take abelacimab before a procedure?

20 Jun 2025

Patients with atrial fibrillation (AF) who have been treated with the long-acting factor XI inhibitor abelacimab may undergo invasive procedures, as shown by the low rates of bleeding in a recent study.

Is it safe to take abelacimab before a procedure?

20 Jun 2025

Analogue bests human insulin in T2D patients with kidney failure

20 Jun 2025 by

Analogue insulin demonstrates superiority over human insulin in terms of survival among patients with kidney failure and type 2 diabetes (T2D) who are receiving peritoneal dialysis, according to a study presented at ERA 2025.

Analogue bests human insulin in T2D patients with kidney failure

20 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

Injectable extended-release naltrexone poses no hepatotoxicity signal in advanced ALD

Injectable extended-release naltrexone poses no hepatotoxicity signal in advanced ALD

Carvedilol trumps propranolol in preventing decompensation in cirrhosis

Carvedilol trumps propranolol in preventing decompensation in cirrhosis

Penpulimab extends survival in R/M nasopharyngeal carcinoma

Penpulimab extends survival in R/M nasopharyngeal carcinoma

IgAN drug hits target in phase III study

IgAN drug hits target in phase III study

Original New Drug Application Approvals by US FDA (16-31 May 2025)

Original New Drug Application Approvals by US FDA (16-31 May 2025)

Onradivir as good as oseltamivir for acute, uncomplicated flu

Onradivir as good as oseltamivir for acute, uncomplicated flu

Bispecific antibody overcomes P. aeruginosa infection in patients with bronchiectasis

Bispecific antibody overcomes P. aeruginosa infection in patients with bronchiectasis

Is it safe to take abelacimab before a procedure?

Is it safe to take abelacimab before a procedure?

Analogue bests human insulin in T2D patients with kidney failure

Analogue bests human insulin in T2D patients with kidney failure